News

Activation Capital Launches Start-the-Journey: Pre-Accelerator Program

Activation Capital proudly announces the launch of Start-the-Journey, a new BioHealth Pre-Accelerator designed to equip early-stage biotech and life science entrepreneurs with the knowledge and tools to build successful startups. Powered by Fat Robin Consulting, this innovative program supports founders in the initial phases of their entrepreneurial journey, preparing them for more advanced initiatives like Activation Capital’s Frontier BioHealth, launched earlier this year to support scaling advanced-stage startups.

The launch of Start-the-Journey comes as Central Virginia’s biotech and life sciences sector continues to thrive. The region has experienced significant advancements, including the growth of its pharmaceutical manufacturing cluster and an expansion of biotech educational programs at local universities. With local research institutions expanding their biotech offerings, Central Virginia is becoming a recognized hub for life sciences innovation. Activation Capital is committed to supporting this ecosystem by helping early-stage entrepreneurs build a solid foundation through Start-the-Journey and its later-stage program Frontier BioHealth.

“This program provides a foundational experience for entrepreneurs navigating the early challenges of building a biohealth startup. Our goal is to help them develop the essential skills needed to succeed,” said Dr. Jim Pannucci, Vice President of Entrepreneurship at Activation Capital.

The program, with content provided by Fat Robin Consulting, includes a personalized intake session for each startup, offering tailored guidance from experts. Cohorts will operate on a rolling model, starting monthly from October 2024 through January 2025. Participants will cover critical topics such as entrepreneurial qualities, market value creation, MVP development, and key resources for entrepreneurs.

Seema Sood, CEO and Founder of Fat Robin Consulting, expressed enthusiasm for the program: “We’re excited to work with founders who are shaping the future of biotech. A strong foundation on entrepreneurship will scaffold the long-term success of young companies.”

Start-the-Journey is ideal for founders in Richmond, across Virginia, or those considering locating their company in the state, with a focus on deep-tech biotechnology, pharmaceuticals, medical devices, and diagnostics. Offered at no cost, the program is designed to reduce financial burdens for early-stage entrepreneurs, and Activation Capital takes no founder equity.

“We’re excited about the potential impact Start-the-Journey will have in fostering innovation and accelerating the growth of Virginia’s BioHealth sector,” Pannucci added. Additional information can be found at https://activation.capital/start-the-journey/.

Start-the-Journey is funded in part through a grant with the U.S. Small Business Administration (SBA). All opinions, conclusions, and/or recommendations expressed herein are those of Activation Capital and do not necessarily reflect the views of the SBA.

Learn more here.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules